Posted by Michael Wonder on 13 Jun 2024
FDA approves Adbry (tralokinumab-ldrm) auto-injector for the treatment of adults with moderate to severe atopic dermatitis
13 June 2024 - Single-dose auto-injector will provide adult patients in the US with an alternative method of administration for Adbry, with the device planned to be available in the coming months.
Leo Pharma has today announced approval from the US FDA for a new Adbry (tralokinumab-ldrm) 300 mg single-dose auto-injector for adult patients.
